fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

New research reveals genomic profile of seborrheic dermatitis and answers key questions on immune response and skin barrier dysfunction – Arcutis Biotherapeutics Inc

Written by | 12 Mar 2024

Arcutis Biotherapeutics, Inc., highlights new research that, for the first time, reveals the gene expression profile of seborrheic dermatitis . The Arcutis sponsored research from The Kimberly and… read more.

Journal of the American Academy of Dermatology publishes Zorvye (roflumilast) foam, 0.3% results for seborrheic dermatitis from pivotal phase III trial – Arcutis Biotherapeutics Inc

Written by | 7 Feb 2024

Arcutis Biotherapeutics, Inc. announced that the Journal of American Academy of Dermatology (JAAD) published positive results from the pivotal Phase III STRATUM trial evaluating Zoryve (roflumilast) foam, 0.3%… read more.

FDA approves Zoryve (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis – Arcutis Biotherapeutics

Written by | 19 Dec 2023

Arcutis Biotherapeutics, Inc. announced the FDA has approved the new drug application (NDA) for Zoryve (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.